SGEN - Seattle Genetics, Inc.
108.31 0.00 (0.00%)
After hours: 4:51PM EST
| Previous Close | 112.11 |
| Open | 111.36 |
| Bid | 100.06 x 900 |
| Ask | 108.40 x 1400 |
| Day's Range | 106.32 - 113.05 |
| 52 Week Range | 62.90 - 124.32 |
| Volume | 959,818 |
| Avg. Volume | 1,086,473 |
| Market Cap | 18.616B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.87 |
| Earnings Date | Apr 22, 2020 - Apr 26, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 125.75 |
- Business Wire
Seattle Genetics to Present at the Cowen 40th Annual Healthcare Conference
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Cowen 40th Annual Healthcare Conference on Tuesday, March 3, 2020 at 9:20 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section.
- American City Business Journals
Seattle Genetics’ bladder drug gets breakthrough therapy designation
Seattle Genetics’ cancer-killing bladder drug, Padcev, has received breakthrough therapy designation from the Federal Drug Administration, the company announced Wednesday. The drug — made by the Bothell-based biotech in partnership with Japanese drug maker Astellas Pharma, which has a Seattle office — gained accelerated approval in December, three months ahead of schedule. Seattle Genetics, which is the largest biotech in the Seattle area based on employee count from 2018, recorded $916.7 million in revenue last year, up from $654.7 million in 2018.
- Zacks
Biotech Stock Roundup: INCY's Solid Q4 Results, EPZM & SGEN's Pipeline Updates
It was a low-key week for the biotech sector with updates from just a few small biotech companies.
- PR Newswire
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for PADCEV™ (enfortumab vedotin-ejfv) in combination with Merck's (known as MSD outside the United States and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting.
- Business Wire
Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer
Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for PADCEV™ (enfortumab vedotin-ejfv) in combination with Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting.
- Business Wire
Seattle Genetics Announces FDA Filing Acceptance for Priority Review of Tucatinib New Drug Application (NDA) for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Company’s New Drug Application (NDA) for the investigational medicine tucatinib. This NDA requests FDA approval of tucatinib in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received at least three prior HER2-directed agents separately or in combination, in the neoadjuvant, adjuvant or metastatic setting. The filing is based on the results of HER2CLIMB, a randomized pivotal trial comparing tucatinib added to trastuzumab and capecitabine versus trastuzumab and capecitabine alone. HER2CLIMB trial results were recently presented at the 2019 San Antonio Breast Cancer Symposium and published in the New England Journal of Medicine (NEJM). Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of August 20, 2020. Tucatinib is an oral, small molecule tyrosine kinase inhibitor (TKI) that is highly selective for HER2.
- Benzinga
The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) AbbVie Inc (NYSE: ABBV ) Acceleron Pharma Inc (NASDAQ: ...
- Business Wire
Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treatment for Advanced Bladder Cancer
Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced updated results from the phase 1b/2 clinical trial EV-103 in previously untreated patients with locally advanced or metastatic urothelial cancer who were ineligible for treatment with cisplatin-based chemotherapy. Forty-five patients were treated with the combination of PADCEV™ (enfortumab vedotin-ejfv) and pembrolizumab and were evaluated for safety and efficacy. After a median follow-up of 11.5 months, the study results continue to meet outcome measures for safety and demonstrate encouraging clinical activity for this platinum-free combination in a first-line setting. Updated results will be presented during an oral session on Friday, February 14 at the 2020 Genitourinary Cancers Symposium in San Francisco (Abstract 441). Initial results from the study were presented at the European Society of Medical Oncology Congress in September 2019.
- Thomson Reuters StreetEvents
Edited Transcript of SGEN earnings conference call or presentation 6-Feb-20 9:30pm GMT
Q4 2019 Seattle Genetics Inc Earnings Call
- Simply Wall St.
Seattle Genetics, Inc. Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Investors in Seattle Genetics, Inc. (NASDAQ:SGEN) had a good week, as its shares rose 8.3% to close at US$117...
- Investopedia
3 Nasdaq 100 Stocks With Excellent Upside Potential
These lesser-known Nasdaq 100 components could post stronger returns than big tech stocks in the coming months.
- Zacks
Seattle Genetics (SGEN) Q4 Earnings Top, Adcetris Drives Sales
Seattle Genetics (SGEN) rides high on Q4 earnings and revenue beat.
- Zacks
Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates
Seattle Genetics (SGEN) delivered earnings and revenue surprises of 51.11% and 29.44%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- Investor's Business Daily
Biotech Giant Crushes Sales Estimates And Posts A Profit — But Shares Dive
On Thursday, Seattle Genetics reported earnings of 14 cents per share on $289.8 million in sales for its fourth quarter ended Dec. 31. In response, SGEN stock skidded in late trading.
- Business Wire
Seattle Genetics Reports Fourth Quarter and Full Year 2019 Financial Results
Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2019. The Company also highlighted ADCETRIS (brentuximab vedotin) and PADCEV (enfortumab vedotin-ejfv) commercial, regulatory and clinical development accomplishments and progress with its clinical programs for cancer, including tucatinib.
- ACCESSWIRE
Seattle Genetics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 6, 2020 / Seattle Genetics, Inc. (NASDAQ:SGEN) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 6, 2020 at ...
- Zacks
Why Seattle Genetics (SGEN) Might Surprise This Earnings Season
Seattle Genetics (SGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- Business Wire
EMA Validates Seattle Genetics’ Marketing Authorization Application for Tucatinib for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for tucatinib, in combination with trastuzumab and capecitabine, for the treatment of adult patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received at least two prior anti-HER2 treatment regimens. The EMA validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. Tucatinib is an oral, small molecule tyrosine kinase inhibitor (TKI) that is highly selective for HER2.
- Zacks
Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Seattle Genetics (SGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Roche's (RHHBY) Lymphoma Drug Polivy Gets Approval in Europe
Roche (RHHBY) obtains approval for Polivy in Europe for the treatment of adult patients with R/R DLBCL.
- Business Wire
Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2019 Financial Results on February 6, 2020
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and full year 2019 financial results on Thursday, February 6, 2020 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
- Business Wire
Seattle Genetics Achieves Milestone Following European Commission Approval of Roche’s Polivy® (Polatuzumab Vedotin)
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it will receive a milestone payment from Roche triggered by European Commission conditional marketing authorisation for Polivy® (polatuzumab vedotin). Polivy is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics’ technology. It was developed and is commercialized by Roche/Genentech. Polivy was approved in combination with bendamustine plus MabThera® (rituximab) (BR) for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not candidates for a haematopoietic stem cell transplant. Polivy was granted PRIME (PRIority MEdicines) designation by the European Medicines Agency (EMA) for the treatment of people with R/R DLBCL in 2017.
- Zacks
Seattle Genetics Up More Than 40% in the Past Year: Here's Why
Seattle Genetics' (SGEN) Adcetris registers strong sales in 2019. The company wins an accelerated approval for Padcev to treat urothelial cancer while other pipeline candidates also progress well.
- Simply Wall St.
How Much is Seattle Genetics, Inc.'s (NASDAQ:SGEN) CEO Getting Paid?
Clay Siegall became the CEO of Seattle Genetics, Inc. (NASDAQ:SGEN) in 2002. First, this article will compare CEO...
